BIOLASE Announces Presentation of Its Technology to National Meeting of Eye Surgeons

IRVINE, CA, Apr 06 (MARKET WIRE) --
BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser
company, today announced that a presentation this week at a national
meeting of eye surgeons will cover the multiple benefits and promising
potential applications that its newest water-based laser technologies
have for eye surgery. Erin Stahl, M.D., a pediatric and refractive
surgeon at Children's Mercy Hospital in Kansas City, will present a
comprehensive paper, outlining benefits such as minimal pain and the
prevention of the flow of bleeding, or hemostasis, to the American
Society of Cataract and Refractive Surgery Symposium and Congress in
Boston, Massachusetts.

In her paper titled "The Use of a Novel, Water-Based Laser to Cut and
Coagulate Anterior Segment Tissue," Dr. Stahl concluded that BIOLASE's
water-based laser technology now well accepted in dentistry "has the
potential to be a multipurpose cutting tool that could be used across
disciplines" in eye surgery. The multiple ophthalmic applications for the
BIOLASE laser technology include presbyopia, plastic surgery, glaucoma,
strabismus (the abnormal alignment of the eyes) and anterior
segment/sclera.

Dr. Stahl noted that, in general, there are similarities to the uses of
water-based laser technologies in dentistry and eye surgery in part
because the tissues in the mouth are very similar to those on and around
the eye. Dr. Stahl has investigated using a YSGG Waterlase Laser created
by BIOLASE to cut various ocular tissues in a laboratory setting.

"The water-based laser device has been very successful in dentistry
because it can cut hard and soft tissue and has a unique way of cutting,
with low inflammation and a lack of bleeding," Dr. Stahl said. "That may
translate into a variety of potential uses for ophthalmology for such
things as bone sculpting and tissue dissection with hemostatis for
plastic surgery, angle surgery for glaucoma, and scleral incisions for
relaxing procedures or implant placement."

The presentation was accompanied by a video provided by Jose Maria
Rodriguez, M.D., an ophthalmologic surgeon at Hospital Ramon Y Caial in
Madrid, Spain. Dr. Rodriguez is a global leader in experimenting with
lasers in eye surgery.

BIOLASE has developed a variety of water-based dental laser systems as
well as the FDA-cleared OCCULASE MD(TM) Laser System, developed
specifically for general ophthalmic soft tissue surgical applications
including presbyopia, or the inability to focus on near objects,
typically due to aging. Presbyopia affects a majority of adults over the
age of 40.

Dr. Stahl is the daughter of Daniel S. Durrie, M.D., a member of the
BIOLASE Board of Directors. She has no personal financial interest in the
Company.

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc.
(http://www.biolase.com), the world's leading dental laser company,
develops, manufactures and markets Waterlase technology and lasers and
related products that advance the practice of dentistry and medicine. The
Company's products incorporate patented and patent pending technologies
designed to provide clinically superior performance with reduced pain and
faster recovery times. BIOLASE's principal products are dental laser
systems that perform a broad range of dental procedures, including
cosmetic and complex surgical applications. Other products under
development address ophthalmology, pain management and other medical and
consumer markets.

This press release may contain forward-looking statements within the
meaning of safe harbor provided by the Securities Reform Act of 1995 that
are based on the current expectations and estimates by our management.
These forward-looking statements can be identified through the use of
words such as "anticipates," "expects," "intends," "plans," "believes,"
"seeks," "estimates," "may," "will," and variations of these words or
similar expressions. Forward-looking statements are based on management's
current, preliminary expectations and are subject to risks, uncertainties
and other factors which may cause the Company's actual results to differ
materially from the statements contained herein, and are described in the
Company's reports it files with the Securities and Exchange Commission,
including its annual and quarterly reports. No undue reliance should be
placed on forward-looking statements. Such information is subject to
change, and we undertake no obligation to update such statements.

For further information, please contact: Jill Bertotti (investor) and Len Hall
(media), of Allen & Caron, +1-949-474-4300.

Copyright 2010, Market Wire, All rights reserved.

-0-